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While de-escalation of bisphosphonates from 4 to 12-weekly dosing has been shown to be clinically non-inferior to
standard dosing, there is evidence the de-escalation is associated with increased bone turnover biomarkers. Here
we evaluated the effect of de-escalated dosing on a panel of biomarkers and determined their association with
incidence of skeletal related events (SREs) in breast cancer patients with ‘low risk’ bone metastases. As part of a pilot
randomized trial, women with baseline C-telopeptide levels <600 ng/L after >3 months of 3–4 weekly pamidronate
were randomized to continue pamidronate every 4 weeks or de-escalation to 12-weekly treatment. Serum was
analysed for bone biomarkers (C-telopeptide, N-telopeptide, bone-specific alkaline phosphatase, transforming
growth factor-β, procollagen type 1 N-propeptide, activinA and bone sialoprotein) using ELISA. The associations
between changes in biomarkers, pain scores and SREs were assessed by univariable logistic regression. Numerical
increases in all biomarkers were observed between baseline and 12 weeks but were of higher magnitude in the
de-escalated arm. Pain scores in the de-escalated treatment arm showed a greater magnitude of pain reduction
from baseline to 12 weeks. Neither baseline levels nor changes in biomarkers from baseline to 12 weeks on treatment
were associated with on study SREs. Baseline pain as measured by the FACT-BP was associated with increased risk of
SRE. In conclusion, biomarkers of bone activity do not appear to predict for SREs in ‘low risk’ cohorts. However, baseline
bone pain appears to be associated with SRE occurrence, a finding which warrants evaluation in larger cohorts.
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Bone is the most common site of metastasis in breast
cancer (Coleman & Rubens 1987) and skeletal metasta-
ses are associated with skeletal related events (SREs)
such as; surgery/radiation to bone, pathological fractures,
spinal cord compression and hypercalcemia. Development
of SREs can significantly impair a patient’s quality of life,
and thus current treatment strategies attempt to prevent
or delay the occurrence of SREs. As the osteoclast is
the primary cell type implicated in bone destruction,
osteoclast-inhibiting agents such as bisphosphonates or
denosumab are essential components of the management* Correspondence: caddison@ohri.ca
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in any medium, provided the original work is pof patients with bone metastases (Clemons et al. 2012;
Coleman 2011; Dougall et al. 2014; Drooger et al. 2013).
Initial studies of bisphosphonates, treated patients
every 3–4 weeks concurrently with chemotherapy. How-
ever, given the long terminal half life of these agents,
and the fact that patients may be treated with them for
years, their dosing frequency has come into question
(Kimmel 2007), leading to a number of trials looking at
de-escalated therapy. To date both single arm (Addison
et al. 2014) and randomized trials (Amadori et al. 2013;
Hortobagyi et al. 2014; Amir et al. 2013) have confirmed
that de-escalated treatment is feasible and at least over
the short term is not associated with a greater risk of
SREs. It is also noteworthy that cumulative exposure to
these drugs is associated with significant toxicities
(Mariotti 2008), which could be reduced with use of de-
escalated treatment strategies. One potential caveat toan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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such as N-telopeptide (NTx) (Amadori et al. 2013) or
C-telopeptide (CTx) (Amir et al. 2013) which are often
used to monitor bone metastases progression appear to
rise more substantially in de-escalated arms. These find-
ings raise questions around the long term safety of de-
escalation of bone targeted therapy.
The REFORM trial was a pilot randomized trial in
which breast cancer patients with bone metastases con-
sidered to be at “low risk” of complications from their
metastases (based on levels of the bone turnover marker
CTx <600 ng/L) were randomized to continue therapy
once every 3–4 weekly (standard) or to de-escalate to
treatment once every 12-weekly for 48 weeks (Amir et al.
2013). The primary analysis comprised changes in serum
CTx, however patients were also followed for the occur-
rence of SREs. While changes in CTx were not associ-
ated with SRE risk in the REFORM trial the utility of
other putative biomarkers of bone activity as predictors
of SREs remain of interest. With availability of longer
follow-up data we now explore a series of bone bio-
markers including CTx (Lipton et al. 2008; Lipton et al.
2011; Coleman et al. 2005), urinary (u)NTx (Rosen et al.
1994; Gorai et al. 1997; Clemens et al. 1997), bone-specific
alkaline phosphatase (BSAP), transforming growth factor
(TGF)-β (Baselga et al. 2008; Desruisseau et al. 2006), pro-
collagen type 1 amino terminal peptide (P1NP) (Garnero
et al. 2000a; Chevrel et al. 2007), activinA (Reis et al.
2002), bone sialoprotein (BSP) (Diel et al. 1999) and pain
scores (Harris et al. 2007; Broom et al. 2009) and their as-
sociation with the incidence of SREs in the REFORM trial.
Materials and methods
Patient cohorts
REFORM was a pilot, randomized, non-inferiority trial
designed to explore the effect of de-escalated bisphos-
phonate therapy on women with breast cancer and bone
metastases who were biochemically defined as being at
low risk of SREs. Women with histologically proven
breast cancer with radiological or biopsy confirmed bone
metastases, CTx levels in the low-risk range (defined as
serum CTx levels in the lowest tertile [<600 ng/L] (Garnero
et al. 2003)), and who had received 3–4 weekly anti-bone
resorption therapy for a minimum of 3 months were eli-
gible for entry into the REFORM study (Amir et al. 2013).
Patients were allocated in an approximate 1:1 fashion to re-
ceive pamidronate 90 mg intravenously every 3–4 weeks
(control group) or every 12 weeks (de-escalated group) for
48 weeks, stratified according to baseline serum CTx
(<400 ng/L and 400-600 ng/L) and duration of prior bis-
phosphonate use (<6 months and >6 months), using a
computer-generated permuted blocks design. As part of the
main study, serum CTx and bone-specific alkaline phos-
phatase (BSAP) levels were measured every 12 weeks for48 weeks. Self-reported pain was also assessed using
the validated Brief Pain Inventory (BPI) and Functional
Assessment of Cancer Therapy Bone Pain (FACT-BP)
questionnaire at baseline and week 12 on study.
Patients allocated to the de-escalated treatment group
who remained with telopeptide levels below 600 ng/L
continued to receive treatment according to protocol-
defined frequency, while patients whose telopeptide
levels rose above 600 ng/L remained on study, but
thereafter received treatment every 3–4 weeks. All
patients received concomitant vitamin D3 (800–1000 IU/
day) and calcium (1200-1500 mg/day) to prevent hypocal-
caemia or secondary hyperparathyroidism. All patients in
the main study were asked to participate in this substudy,
and only those patients who consented to use of collected
specimens for research purposes are included in the
present analysis. The study was conducted in accordance
with REMARK recommendations for biomarker analyses
(McShane et al. 2005), and under institutional ethics
approval.Biochemical analyses
Serum samples collected after an overnight fast, were
allowed to clot for at least 30 minutes then centrifuged
at 3,000 rpm for 10 minutes at room temperature.
Samples were then processed immediately and stored
at −80°C. Serum CTx was measured in a central lab fa-
cility with an enzyme-linked immunosorbent assay
(ELISA; Beta-Cross Laps/serum assay, Roche Diagnos-
tics Canada Inc, Laval, QC; detection limit 10 ng/L,
interassay variability, ~6.7%). Serum BSAP was also
measured in a central lab facility by ELISA (Metra
Biosystems, San Diego, CA; detection limit 0.7 IU/L,
interassay variability ~5.2%). Experimental determin-
ation of serum levels of TGF-β (Quantikine, R&D
Systems, Minneapolis MN, detection limit 20 pg/ml,
interassay variability ~8.3%), activinA (Quantikine, R&D
Systems, Minneapolis MN, detection limit 4 pg/ml, inter-
assay variability ~5.9%), P1NP (USCN Life Science Inc.,
Wuhan China, detection limit 15 pg/ml, interassay
variability ~12%), and BSP (Cusabio Biotech Co., Wuhan
China, detection limit 2 ng/ml, interassay variability ~12%)
were also experimentally measured by ELISA. Urine
NTx levels were measured using the Osteomark
assay system (Alere, Scarborough ME, detection limit
2nM BCE/mM creatine, interassay variability ~6.9%).
All samples were measured in duplicate and concen-
trations determined following interpolation of stand-
ard curves generated from known quantities of
recombinant protein. When values were below the
threshold of detection for each respective assay, con-
centrations were assigned as 0.1 below the sensitivity
threshold for purposes of statistical analysis.
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Descriptive statistics were used to summarize patient
characteristics and laboratory measurements across
time points. Spearman correlation coefficients were
used to investigate for the potential of intra-biomarker
variability and to examine potential relationships be-
tween different biomarkers at each time point. Univari-
able logistic regression analysis was conducted to
determine the association between selected biomarkers
and clinical characteristics and SREs. Multivariable
analysis was not conducted due to the small sample
size. The nonparametric Mann–Whitney U test was
used to test for differences in biomarkers at different
time points between cohorts. Statistical significance
was defined as a p-value of 0.05 or less, and all tests
were two-sided. As this study is exploratory no adjust-
ment for multiple testing was made and validation of
results from additional studies are required.Figure 1 Consort diagram for the REFORM biomarker substudy.Ethical standards
This study was performed in accordance with ethical
standards approved by the Ottawa Health Science Net-
work Research Ethics Board (20120403-01H) and the
University Health Network (08-0513-C).
Results
Patient cohorts
Thirty of the 38 patients (79%) who were randomized
to the original study provided consent for this substudy
(see Figure 1). Of these 30 patients, 13 were random-
ized to Group 1 (q3-4 weekly) and 17 to Group 2 (12
weekly). Samples were available at week 12 post study
entry for 10 patients from Group 1 and 13 from Group
2. Patients were followed for 2 years (one year on study
and one additional year of follow up for which fre-
quency of pamidronate use was not specified) during
which time seven SREs were observed among the 25
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group and 4 patients in the experimental group.Biomarker correlations
As each biomarker was measured in duplicate, the intra-
biomarker variability was evaluated. The Spearman cor-
relation coefficient exceeded ρ = 0.92 between duplicated
measurements for each biomarker at each time point,
indicating little to no intra-biomarker variability. Thus,
the addition of the duplicate measure added little to no
additional information, and as a result, only the first bio-
marker value is discussed for all further analyses.
The association between different biomarkers at base-
line and at week 12, the association of baseline and week
12 biomarker values, as well as the association of the
change from baseline to week 12 between different bio-
markers, are presented in Additional files 1 and 2: Tables
S1 (baseline) and S2 (week 12) respectively. Generally,
only weak to moderate correlations were observed be-
tween the different biomarker measures. Baseline CTx and
BSAP were strongly associated with week 12 measures,
while baseline NTx, P1NP, TGF-β and activin-A were all
moderately associated for their values at week 12.
Biomarker values at baseline and at week 12 were gen-
erally similar between the two treatment arms (Table 1).
As can be seen in Table 2, those patients with higher
levels of baseline CTx (p = 0.002), BSAP (p = 0.005),
P1NP (p = 0.002) and ActivinA (p < 0.001) were signifi-
cantly more likely to not complete week 12 of the study.
It is noted that CTx > 600 ng/L was a trial mandated rea-
son for coming off study early.Table 1 Biomarker and clinical characteristics
Baseline
All patients Group 1
N 30 13
CTx ng/L Median (IQR) 191 (104, 387) 142 (117, 28
BSAP IU/L Median (IQR) 18 (14, 30) 16 (14, 30
TGF-β, ng/ml Median (IQR) 22.5 (17.1, 26.3) 24.8 (20.7, 26
Activin-A, pg/ml Median (IQR) 597 (419, 1528) 795 (517, 11
NTx 2nM BCE/mM creatine Median (IQR) 158 (73, 282) 159 (60, 29
P1NP ng/ml Median (IQR) 56 (48, 91) 70 (48, 96
BSP ng/ml Median (IQR) 34 (13, 60) 39 (10, 73
FACT-BP Median (IQR) 13 (5, 25) 8 (5, 14)
BPI Median (IQR) 16 (0, 32) 4 (0, 29)
# of SRE (%), on or
post study (n = 25)
0 11 (44.0) 5 (45.5)
1 9 (36.0) 3 (27.7)
2 5 (20.0) 3 (27.7)
3The change in biomarker levels from baseline to week
12 on study was assessed, given that week 12 levels are
often used in clinical trials as a surrogate marker of bone
metastasis control and hence bisphosphonate efficacy
(Lipton et al. 2008; Coleman et al. 2005; Brown et al.
2003; Lipton et al. 1998). Significant increases in bio-
marker levels from baseline to week 12 for CTx (p <
0.001), BSAP (p = 0.011) and activinA (p = 0.001) were
noted for the entire cohort of patients i.e. whether or
not they were randomized to de-escalated therapy
(Table 3). Comparing between treatment arms, patients
in treatment group 2 (q12 weekly arm) had statistically
significantly greater increases in CTx (median of 131
versus 17, p = 0.034) and in BSAP (median = 3 versus 0,
p = 0.010).
Association between biomarkers and pain
Baseline pain scores tended to be higher in patients ran-
domized to 12-weekly therapy (p = 0.051 for FACT-BP
and p = 0.12 for BPI), but pain scores were similar at the
week 12 time point (p = 0.64 for FACT-BP and p = 0.55
for BPI). Interestingly, pain scores as measured by both
FACT-BP (p = 0.053) and BPI (p = 0.050) tended to be
more reduced from baseline to 12 weeks in the patients
treated with the de-escalated regimen as compared to
3–4 weekly treated patients (Table 3), although it is
noted that the p-value was low and did not attain the
pre-defined level of statistical significance.
Association between biomarkers and SRE incidence
Results from univariable exploratory analyses to determine
whether circulating levels of biomarkers were significantlyWeek 12




17 23 10 13
7) 218 (88, 387) 223 (106, 381) 155 (106, 225) 308 (179, 423)
) 18 (14, 29) 17 (14, 29) 16 (12, 29) 18 (16, 25)
.3) 20.3 (17.1, 25.5) 21.5 (15.8, 26.6) 21.7 (15.0, 26.6) 21.5 (18.0, 25.7)
64) 519 (404, 1666) 560 (483, 1045) 616 (483, 1153) 560 (526, 755)
8) 149 (87, 268) 258 (121, 338) 299 (94, 338) 230 (137, 342)
) 55 (4, 80) 54 (38, 75) 55 (36, 75) 54 (52, 60)
) 32 (16, 55) 17 (5, 21) 18 (16, 21) 14 (5, 36)
16 (11, 26) 13.5 (8, 18) 11 (8, 17) 14 (11, 18)
19 (6, 57) 14.5 (2, 21) 13 (1, 20) 15 (7, 21)
6 (42.9) 18 (72.0) 8 (72.7) 10 (71.4)
6 (42.9) 3 (12.0) 2 (18.2) 1 (7.1)
2 (14.3) 3 (12.0) 1 (9.1) 2 (14.3)
1 (4.0) 0 (0.0) 1 (7.1)
Table 2 Factors associated with failure to complete 12 weeks on study
Did not complete week 12 Completed week 12 p-value
N 7 23
CTx Median (IQR) 656 (492, 811) 141 (88, 229) 0.002
BSAP Median (IQR) 44 (26, 68) 15 (14, 22) 0.005
TGF-β, ng/ml Median (IQR) 26.3 (16.8, 30.7) 20.7 (17.1, 25.5) 0.38
Activin-A, pg/ml Median (IQR) 2922 (1666, 9576) 517 (404, 775) <0.001
NTx Median (IQR) NA 158 (73, 282) -
P1NP Median (IQR) 123075 (80014, 178930) 54334 (36692, 77623) 0.002
BSP Median (IQR) 63.9 (55.3, 90.4) 15.9 (8.2, 32.9) 0.004
FACT-BP Median (IQR) 15 (7, 36) 12 (5, 23) 0.37
BPI Median (IQR) 57 (12, 65) 6 (0, 29) 0.049
# of SRE, pre, study (n = 25) 0 1 10
1 0 9
2 1 4




Duration of bone mets, in months Median (IQR) 28 (18, 41) 18 (12, 29) 0.19
Time from primary to bone mets (n = 25) <2 years 1 12
2–5 years 0 5
>5 years 1 6
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SREs versus those that did not are shown in Table 4.
Interestingly, 6/14 (43%) patients who had previous
SREs prior to study entry, had an on study SRE, while
only 1/11 (9%) without a prior SRE experienced an on
study SRE (p-value = 0.088). At 2 years of follow up,
SRE rates remained similar between the two cohorts,
with 3/11 (27%) of 3–4 weekly treated patients and 4/14
(29%) of 12 weekly treated patients having experienced
SREs (p-value = 0.94).Table 3 Changes in biomarker levels from baseline to 12-wee
Difference all patients
N 23
CTx ng/L Median (IQR) 83 (2, 155)
BSAP IU/L Median (IQR) 1 (0, 4)
TGF-β, ng/ml Median (IQR) 0.8 (−2.1, 4.9)
Activin-A, pg/ml Median (IQR) 111 (28, 526)
NTx 2nM BCE/mM creatine Median (IQR) 42 (−48, 168)
P1NP ng/ml Median (IQR) 5742 (−6694, 19129)
BSP ng/ml Median (IQR) 5.8 (−8.0, 9.5)
FACT-BP Median (IQR) 0 (−4, 3)
BPI Median (IQR) 0 (−3, 4)No significant association was observed for any of the
baseline biomarkers, including the more commonly used
markers such as CTx and NTx (Table 4), as prognostic
factors for experiencing a SRE. Similarly, the change in
level from baseline to week 12 was not significantly asso-
ciated with experiencing on study SREs for any bio-
marker (Table 4). Of all the parameters measured, only
baseline pain as measured by FACT-BP was statistically
significantly associated with development of an on or







<0.001 17 (−27, 83) 131 (79, 171) 0.034
0.011 0 (−1, 1) 3 (2, 5) 0.010
0.28 −0.1 (−2.1, 2.2) 2.4 (−0.0, 4.9) 0.41
0.001 96 (−29, 596) 122 (34, 256) 0.60
0.15 42 (−15, 179) 45 (−76, 108) 0.54
0.24 1376 (−6694, 8498) 16539 (−1266, 21993) 0.26
0.63 0.5 (−15.4, 6.4) 9.8 (0.8, 47.2) 0.14
0.99 1 (0, 4) −2 (−4, 1) 0.053
0.94 2 (0, 7) −1 (−8, 1) 0.050
Table 4 Association of biomarkers with odds of having an on or post-study SRE
Baseline Change from Baseline to 12 Weeks
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
CTx /10 unit change 1.00 (0.94, 1.07) 0.99 1.04 (0.95, 1.14) 0.39
BSAP /unit change 1.03 (0.97, 1.09) 0.36 0.90 (0.73, 1.11) 0.32
TGF-β /unit change 1.05 (0.90, 1.23) 0.54 0.98 (0.83, 1.16) 0.83
Activin-A /100 unit change 0.98 (0.89, 1.07) 0.60 0.99 (0.93, 1.04) 0.64
NTx /10 unit change 1.00 (0.97, 1.02) 0.69 1.01 (0.97, 1.06) 0.56
P1NP /10000 unit change 0.97 (0.79, 1.18) 0.75 0.98 (0.80, 1.20) 0.84
BSP /10 unit change 1.00 (0.63, 1.60) 0.99 0.94 (0.60, 1.47) 0.79
FACT-BP /unit change 1.13 (1.01, 1.28) 0.041 0.99 (0.87, 1.14) 0.93
BPI /unit change 1.03 (0.99, 1.08) 0.16 1.00 (0.94, 1.06) 0.93
Duration of bone metastases /month 1.03 (0.99, 1.08) 0.14
Pre-Study SRE Yes versus no 7.50 (0.74, 75.72) 0.088
Treatment Group 2 versus 1 1.07 (0.18, 6.21) 0.94
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BP, were not associated with SRE development (Table 4).
Discussion
De-escalated bisphosphonate therapy is being increas-
ingly utilized after data from the large randomized
ZOOM and OPTIMIZE-2 trials showed that skeletal
outcomes are similar to those of patients receiving
standard 3–4 weekly treatment (Amadori et al. 2013;
Hortobagyi et al. 2014). As confirmed in our present
study, a common feature of studies of de-escalated bis-
phosphonate therapy appears to be modest increases in
telopeptide levels from baseline to week 12 in the de-
escalated arm, while levels are maintained in the stand-
ard frequency arm. Despite this, no differences in either
the number of SREs (REFORM (Amir et al. 2013) and
current study), time to first on-study SRE (ZOOM
(Amadori et al. 2013)) or SRE rate (OPTIMIZE-2
(Hortobagyi et al. 2014)) were observed between the two
treatment groups. This raises the question of whether or
not circulating telopeptide levels on treatment are truly
related with SRE risk. With the continuing trend of clin-
ical studies being designed to use measurement of these
markers as endpoints to determine drug efficacy, and
the fact that patients on these drugs experience SREs
regardless of the level of telopeptides, it is of the ut-
most importance to gain a better understanding of the re-
lationship between biomarker measures and subsequent
SRE risk.
In the current analysis a range of recognized bone-
turnover or metastasis biomarkers were measured. Urinary
N-telopeptide (uNTx) is a fragment of collagen I produced
during osteolysis of the bone and has frequently been
used to monitor bone resorption in both osteoporotic
(Yoshimura et al. 2011; Garnero 2008; Reginster et al. 2001)and bone metastases (Lipton et al. 2008; Lipton et al. 2011;
Coleman et al. 2005) patients. Elevated levels of uNTx have
been shown to correlate with bone turnover (Rosen et al.
1994; Gorai et al. 1997; Clemens et al. 1997). P1NP is a
marker of bone formation (Garnero et al. 2000b) which has
been shown to correlate with presence of bone metastases
in prostate cancer patients (Garnero et al. 2000a), and pre-
viously was shown to be associated with increased bone
fractures (Chevrel et al. 2007). TGF-β plays a critical role in
the exacerbation of osteolytic metastatic disease by contrib-
uting to continued osteoclast activity and aggressive and
invasive tumour phenotypes (Ivanovic et al. 2003). Further-
more, plasma TGF-β levels have been found to correlate
with disease stage and bone metastasis in breast cancer
(Baselga et al. 2008; Desruisseau et al. 2006). Similarly re-
cent studies have suggested that the TGF-β family member,
activinA, also plays a role in metastatic and osteoclastic
processes (Leto et al. 2006; Risbridger et al. 2001; Fuller
et al. 2000). Plasma levels of activinA were shown to be
higher in breast cancer patients with bone metastases as
compared to those without and to positively correlate with
the number of bone metastases (Reis et al. 2002). Lastly,
tumour-derived expression of BSP also correlates with sub-
sequent development of osseous metastases, as it has been
shown that baseline serum BSP levels were elevated
in ~90% of women who went on to develop bone metasta-
ses, while not elevated in patients who developed visceral
metastases (Diel et al. 1999).
None of the measured parameters at baseline nor their
changes from baseline to week 12, were observed to pre-
dict for subsequent SREs. The fact that other more rou-
tinely used markers such as CTx and uNTx were not
significantly different in patients who experienced SRE
versus those that did not in our study may simply be a
result of the fact that these cohorts were too small to
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have suggested that median levels of many bone turn-
over biomarkers tend to be higher in the patients who
experienced SREs (Coleman et al. 2008), additional stud-
ies lead us to question this notion in bone metastatic pa-
tients considered to be low risk due to bone turnover
markers closer to the ‘normal range’. Recent results with
NTx have suggested that in patients with uNTx levels
considered to be in the low range, >90% of the patients
who experienced SREs had no documented increase in
NTx prior to their SRE (Lipton et al. 2013). A further
possibility is that in patients with low baseline levels of
telopeptides changes in these markers are not predictive
of bone outcomes. It remains unclear if this observation
can be extrapolated to patients with higher baseline bio-
marker levels.
Of all the parameters measured in the current study, it
is interesting that pain at baseline was prognostic for
occurrence of subsequent SREs. Previous analyses in
metastatic breast cancer patients treated with the bis-
phosphonate zoledronic acid, also found that baseline
pain was associated with time to first SRE in univariable
analysis (Brown et al. 2010). However, in this study, pain
was not associated with skeletal fractures, but was sig-
nificantly associated with need for radiation treatment.
Of the 7 patients who experienced SREs in REFORM all
required radiotherapy (although each may have had add-
itional SREs of other types in conjunction), which may
explain the observed association between baseline pain
and occurrence of SREs. Despite this, given that pain sig-
nificantly affects a patient’s quality of life and is associated
with need for radiation treatment for skeletal complica-
tions, its measurement in future studies is warranted.
With data suggesting that de-escalation of bisphospho-
nate therapy may be equally therapeutically effective yet
also spare patients exposure to the detrimental effects of
excessive cumulative dose of bisphosphonates (Amadori
et al. 2013; Amir et al. 2012), it is essential to better
understand the pharmacodynamics of bone turnover
markers in response to these agents if clinical decisions
are to be made based on these factors. While markers
such as NTx and CTx may be very effective as prognos-
tic indicators of bone turnover in patients with bone
metastases starting bone targeted therapies, additional
markers assessing risk of SRE may be required. This may
be particularly important in those cases where patients
are found to have NTx and CTx levels considered to be
in the “low” or “normal” range with bone-targeted treat-
ments. Furthermore, it is unclear what effects concomi-
tant anti-cancer therapy may have on the relative levels
of these markers that may further confound their utility
as predictive markers on treatment. Recent studies have
shown that use of exemestane results in increased levels
from baseline for BSAP, P1NP and CTx, while additionof everolimus to exemestane resulted in decreased levels
of the same biomarkers after baseline (Gnant et al.
2013). Importantly, the changes in biomarker levels were
observed in patients irrespective of the presence of bone
metastases, highlighting the effect of chemotherapy on
normal bone homeostasis in general. Interestingly, a
large recent biomarker driven study in patients starting
fulvestrant also showed significant decreases in uNTx
from baseline to on treatment (Clemons et al. 2014). As
these patients had no change in their bone-targeted
therapy at the time of study entry, this confirms that
changes in anticancer therapies can alter bone bio-
marker levels.
This study has a number of limitations. It was specific-
ally designed as a small study to assess the feasibility of
randomizing patients to de-escalated therapy. As such it
has a small cohort and even with the extended follow
up, a low number of SREs has occurred. Furthermore, 5
patients were lost to follow up over the year following
the end of the REFORM study, further restricting our
sample size. It is also of interest to note that only pain
as assessed by FACT-BP but not by BPI was associated
with SRE occurrence, despite both tests being validated
measurement tools. The reasons for this remain unclear.
Finally, all patients enrolled in our study had low base-
line levels of CTx and therefore, our results may not be
generalizable to patients with bone metastases who
present with a greater magnitude of bone resorption.
Conclusions
In conclusion, these findings show that no significant
changes in any of the biomarkers tested were observed
between the standard and the de-escalated treatment
groups. Exploratory analysis suggested that biomarkers
of bone activity do not appear to predict for SREs in the
‘low risk’ bone metastases patients. Bone pain does how-
ever appear to be associated with SRE occurrence, a
finding which warrants evaluation in larger studies.
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